Open AccessEffect of two different early rescue surfactant treatments on mortality in preterm infants with respiratory distress syndrome
Author(s) -
Kadıoğlu Şimşek Gülsüm,
Kanmaz Kutman Hayriye Gözde,
Canpolat Fuat Emre,
Oğuz Şerife Suna
Publication year - 2020
Publication title -
the clinical respiratory journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.789
H-Index - 33
eISSN - 1752-699X
pISSN - 1752-6981
DOI - 10.1111/crj.13130
Subject(s) - medicine , respiratory distress , gestational age , pediatrics , incidence (geometry) , neonatal respiratory distress syndrome , birth weight , surfactant therapy , anesthesia , pregnancy , physics , biology , optics , genetics
Although current evidence suggests that initial dose of 200 mg/kg poractant alfa reduces mortality in the treatment of respiratory distress syndrome (RDS), these data were obtained in a highly heterogeneous group of patients and neither of them addressed mortality as primary outcome. Objective The aim of this study was to investigate the effects of poractant alfa and beractant on mortality when administered as early rescue surfactant therapy in very preterm infants. Methods We retrospectively evaluated preterm infants followed in our unit between May 2017 and November 2018 whose gestational age (GA) was ≤28 weeks and received surfactant within the first 2 hours of life. Morbidities and mortality rates were compared between infants who received initial doses of 200 mg/kg poractant alfa and 100 mg/kg beractant. Results Data from 200 infants who met the inclusion criteria were analyzed. There were 112 patients in the poractant alfa group and 88 patients in beractant group. Mean gestational age in these groups was 26 ± 2 and 25.8 ± 1.8 weeks ( P = 0.45) and mean birth weight was 812 ± 243 and 840 ± 208 g ( P = 0.39), respectively. The poractant alfa and beractant groups had similar rates of overall mortality (53.5% vs 56.8%), mortality in first 7 days (30.5% vs 25.8%), and beyond day 7 (16.4% vs 13.3%) ( P > 0.05). There were no differences in the incidence of preterm morbidities among the two groups. Conclusion We were unable to demonstrate the superiority of poractant in terms of mortality in very preterm infants with RDS. These findings need to be supported by multicenter, randomized controlled trials.